As an essential part of the biopharma value chain, contract development and manufacturing organizations (CDMOs) help companies not only expedite a molecule from its early stage to commercialization, but also navigate complex processes with confidence. Samsung Biologics, a global CDMO with its headquarters in South Korea, offers its state-of-the-art services to pharmaceutical companies who would much rather spend their time on research and discovery. Using its multi-scale, cGMP-compliant facilities, Samsung Biologics ensures seamless development and manufacturing services where needed.
End-to-End CDMO Services
Samsung Biologics invested $1.7 billion into expanding and building an additional facility in South Korea. This new “Super Plant” is currently undergoing construction and upon its full completion in 2023, will make up a quarter of the global total biopharma CMO capacity.
Samsung Biologics’ fourth plant will offer the most up-to-date processes – Pharma 4.0-enabled technology will create an atmosphere that enables data integrity, and multiple operation modes will allow Samsung Biologics to continue offering the best production efficiency. This state-of-the-art facility will be equipped with innovative, top-of-the-line manufacturing technologies.
Furthermore, Samsung Biologics is adding an mRNA drug substance suite to its current site by the first half of 2022 to diversify its service offerings. The new addition to the Songdo facility will allow the CDMO to offer pharmaceutical companies end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish including labeling and packaging, along with cold chain storage.
Samsung Biologics has navigated the past ten years in business with an unwavering commitment to its vision “to enrich human life with technology and innovation.”.
CEO John Rim said, “With a steadfast vision and unrelenting drive to achieve better life for all, we embrace responsibility, expertise, and pride in our work, and will continue on our noble mission to enable improved accessibility of biomedicines and consequently the quality of life for people around the globe.”
Partnerships with Many Companies
Moderna, GSK, and Eli Lilly have all partnered with Samsung Biologics in some way to manufacture and distribute the highest quality biomedicines.
Samsung Biologics has gone above and beyond to maintain its current business relationships, as well as establish new ones in a changing world.
Facing claim issues in Las Vegas is very common. Financial companies are innovative, and they…
Let me paint a picture for you. Imagine you're strolling along, carefree, on a beautiful…
In the field of financial management softwares, being cheap to use is key to being…
In the fast-service restaurant world, being first and staying ahead on the latest technology trends…
Nestled in the picturesque Douro Valley, Peso da Réguaへの特価ツアー情報 is a charming town renowned for…
Office furniture plays a crucial role in shaping the work environment and has a significant…
This website uses cookies.